Rocket Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Rocket Pharmaceuticals, Inc. (RCKT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $4.70M, a 42.14% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.75M.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$967.00K, a 224.94% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$12.25M, a 486.22% decline year-over-year.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$10.35M, a 270.61% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $6.07M, a 40.21% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $10.15M, a 4.89% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $9.67M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.05M 10-Q · filed 2026-08-10 | -$2.02M derived: sum of 3 quarters · filed 2026-08-10 | -$14.26M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$5.75M 10-Q · filed 2026-05-07 | -$6.72M derived: sum of 2 quarters · filed 2026-05-07 | -$18.96M derived: sum of 3 quarters · filed 2026-05-07 | -$10.84M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | -$967.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$13.21M derived: sum of 2 quarters · filed 2026-02-26 | -$5.09M derived: sum of 3 quarters · filed 2026-08-10 | -$10.35M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$12.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.13M derived: sum of 2 quarters · filed 2026-08-10 | -$9.38M 10-Q · filed 2025-11-06 | -$8.61M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $8.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.86M 10-Q · filed 2026-08-10 | $3.64M derived: sum of 3 quarters · filed 2026-08-10 | $6.81M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | -$5.26M 10-Q · filed 2026-05-07 | -$4.48M derived: sum of 2 quarters · filed 2026-05-07 | -$1.31M derived: sum of 3 quarters · filed 2026-05-07 | $3.22M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.94M derived: sum of 2 quarters · filed 2026-02-26 | $8.48M derived: sum of 3 quarters · filed 2026-02-26 | $6.07M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.71M derived: sum of 2 quarters · filed 2025-11-06 | $5.29M 10-Q · filed 2025-11-06 | $21.05M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $4.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.12M 10-Q · filed 2025-08-07 | $17.88M derived: sum of 3 quarters · filed 2025-08-07 | $16.75M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$2.41M 10-Q · filed 2025-05-08 | $13.35M derived: sum of 2 quarters · filed 2025-05-08 | $12.21M derived: sum of 3 quarters · filed 2025-05-08 | $15.48M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.62M derived: sum of 2 quarters · filed 2025-02-27 | $17.90M derived: sum of 3 quarters · filed 2025-02-27 | $10.15M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.14M derived: sum of 2 quarters · filed 2024-11-07 | -$5.61M 10-Q · filed 2024-11-07 | -$3.13M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.48M 10-Q · filed 2024-08-06 | -$1.99M derived: sum of 3 quarters · filed 2025-02-27 | $2.65M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | -$7.75M 10-Q · filed 2024-05-07 | -$5.26M derived: sum of 2 quarters · filed 2025-02-27 | -$624.00K derived: sum of 3 quarters · filed 2025-02-27 | $2.42M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.13M derived: sum of 2 quarters · filed 2025-02-27 | $10.16M derived: sum of 3 quarters · filed 2025-02-27 | $9.67M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.68M derived: sum of 2 quarters · filed 2023-11-07 | $7.19M 10-Q · filed 2023-11-07 | $5.20M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-06-30 | $3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.55M 10-Q · filed 2023-08-09 | $563.00K derived: sum of 3 quarters · filed 2024-02-27 | $6.70M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | -$491.00K 10-Q · filed 2023-05-05 | -$2.48M derived: sum of 2 quarters · filed 2024-02-27 | $3.66M derived: sum of 3 quarters · filed 2024-02-27 | -$12.37M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.16M derived: sum of 2 quarters · filed 2024-02-27 | -$11.87M derived: sum of 3 quarters · filed 2024-02-27 | -$4.83M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $6.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$9.89M derived: sum of 2 quarters · filed 2022-11-04 | -$2.84M 10-Q · filed 2022-11-04 | $6.42M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | -$16.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$8.98M 10-Q · filed 2022-08-09 | $281.00K derived: sum of 3 quarters · filed 2023-02-28 | $5.22M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $7.05M 10-Q · filed 2022-05-06 | $16.31M derived: sum of 2 quarters · filed 2023-02-28 | $21.25M derived: sum of 3 quarters · filed 2023-02-28 | $19.99M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $9.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $14.20M derived: sum of 2 quarters · filed 2023-02-28 | $12.95M derived: sum of 3 quarters · filed 2023-02-28 | $11.02M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $4.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $3.68M derived: sum of 2 quarters · filed 2021-11-05 | $1.75M 10-Q · filed 2021-11-05 | -$2.95M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$3.19M 10-Q · filed 2021-08-09 | -$7.89M derived: sum of 3 quarters · filed 2022-02-28 | -$3.65M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$1.93M 10-Q · filed 2021-05-10 | -$6.63M derived: sum of 2 quarters · filed 2022-02-28 | -$2.39M derived: sum of 3 quarters · filed 2022-02-28 | -$4.57M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | -$4.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$457.00K derived: sum of 2 quarters · filed 2022-02-28 | -$2.64M derived: sum of 3 quarters · filed 2022-02-28 | -$2.72M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $4.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.06M derived: sum of 2 quarters · filed 2020-11-06 | $1.98M 10-Q · filed 2020-11-06 | $7.06M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | -$2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$2.27M 10-Q · filed 2020-08-05 | $2.81M derived: sum of 3 quarters · filed 2021-03-01 | $2.96M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | -$84.00K 10-Q · filed 2020-05-08 | $4.99M derived: sum of 2 quarters · filed 2021-03-01 | $5.14M derived: sum of 3 quarters · filed 2021-03-01 | $7.95M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.22M derived: sum of 2 quarters · filed 2021-03-01 | $8.04M derived: sum of 3 quarters · filed 2021-03-01 | $5.89M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.96M derived: sum of 2 quarters · filed 2019-11-08 | $812.00K 10-Q · filed 2019-11-08 | $2.74M 10-Q · filed 2018-11-09 | $3.05M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $665.00K 10-Q · filed 2019-08-08 | $1.26M 10-Q · filed 2018-08-14 | $2.91M derived: sum of 3 quarters · filed 2019-08-08 | $3.51M derived: sum of 4 quarters · filed 2019-08-08 | ||
| 2018-03-31 | -$2.15M 10-Q · filed 2019-05-09 | -$2.26M 10-Q · filed 2018-05-11 | $96.00K derived: sum of 2 quarters · filed 2019-05-09 | $699.00K derived: sum of 3 quarters · filed 2019-05-09 | $949.00K derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $2.84M derived: sum of 2 quarters · filed 2019-03-08 | $3.09M derived: sum of 3 quarters · filed 2019-03-08 | $2.81M 10-K · filed 2019-03-08 | |||
| 2017-09-30 | $603.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $853.00K derived: sum of 2 quarters · filed 2018-11-09 | $571.00K 10-Q · filed 2018-11-09 | ||||
| 2017-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$32.00K 10-Q · filed 2018-08-14 | |||||
| 2017-03-31 | -$282.00K 10-Q · filed 2018-05-11 | ||||||
| 2016-12-31 | $1.44M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |